Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Strong Trading Volume – Here’s What Happened

Fresenius SE & Co. (OTCMKTS:FSNUY) shares saw strong trading volume on Wednesday. 1,102,757 shares traded hands during trading, an increase of 559% from the previous session’s volume of 167,361 shares. The stock last traded at $12.45 and had previously closed at $12.08.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company presently has an average rating of “Buy”.

Fresenius SE & Co. Trading Up 2.9%

The company has a debt-to-equity ratio of 0.41, a current ratio of 1.28 and a quick ratio of 0.97. The business’s 50-day moving average price is $13.09 and its two-hundred day moving average price is $12.35. The company has a market capitalization of $28.00 billion, a price-to-earnings ratio of 15.73 and a beta of 0.60.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $6.91 billion for the quarter, compared to the consensus estimate of $6.65 billion. Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. Research analysts predict that Fresenius SE & Co. will post 1.08 earnings per share for the current year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.